MMOOZZGG.com

AI investment

AI healthcare investment: who invests and how much

5 min read6 sources

AI healthcare investment is flowing both worldwide and in Russia: in May 2026, Roche bought the AI company PathAI for more than $750 million. Below are the deals, market estimates, Russian figures and the processes where AI already saves doctors’ time.

On this page · 5 sections

The market in numbers

Kama Flow, a Russian analytics firm, values the potential of medtech in Russia by 2030 at $840 million. It is the third segment on its list, after industrial AI ($1.1 billion) and AI agents with process automation ($940 million).

By the same estimate, the available segments of the Russian AI market add up to more than $6.8 billion by 2030. Kama Flow calculates that an independent AI market needs about $1 billion of private venture money a year.

Actual investment is more modest than the estimates. According to Venture Guide, medicine received $20 million in 16 venture deals in the first 9 months of 2026, more than corporate software ($19 million in 20 deals).

This sum covers the whole medical niche, not only AI. You cannot compare it directly with the $840 million estimate: one figure describes deals over 9 months, and the other the potential of the segment by 2030.

For a clinic owner, the market numbers mean one thing: solutions for typical doctor tasks already receive investor money and come to market. Your task is to choose a process and check the effect on your own data, not on a supplier’s presentation.

Deals

The largest purchase of the year in medical AI took place in May 2026: Roche bought PathAI for more than $750 million, according to Solganick.

The purchase fits the general growth of the market. About 305 deals with AI companies took place worldwide in the first quarter of 2026, 90% more than a year earlier.

Venture funds invest in services that already have revenue and users. In January 2026, OpenEvidence, an AI reference tool for doctors, raised $250 million at a valuation of $12 billion, twice the earlier one.

The company reported annual revenue of $100 million and said that more than 40% of US doctors use its service. Here the investor pays for proven use, not for a promise.

Both deals show what buyers and funds pay for: a product that doctors already use, with clear revenue. For a clinic, this is a good filter when choosing a supplier: ask how many doctors use the solution every day.

All rounds with amounts and sources are in our deal tracker. The year’s company purchases are covered on the page about AI acquisitions in 2026.

Russia

In Russia, medical AI looks for money not only from venture funds. A Russian developer of AI services for medicine plans to raise $1.8 million from qualified investors.

The deal is organized by the BITL group, and the shares are placed on the Zorko platform. The round was announced on 29 September 2026 and had not closed by the date of the news.

Venture Guide says Russia’s medical venture market gave $20 million in 16 deals in the first 9 months of 2026. Corporate software and industrial technology each received about $19 million in the same summary.

For a clinic or a clinic network, this means more Russian medical AI suppliers will appear. When you choose a supplier, ask where patient data is stored: under 152-FZ, Russia’s personal data law, it must stay in Russia.

The overall picture for the country is on the page about AI investment in Russia.

Where it pays back

AI in medicine already has a measured effect in documentation. A JAMA study (April 2026) compared more than 1,800 doctors with an AI assistant and 6,770 doctors without it in five US medical centers.

The AI assistant cut documentation time by 16 minutes for every 8 hours of appointments and added 0.5 appointments a week.

For doctors who turned the assistant on in at least half of their appointments, time in the electronic medical record fell by 21.3 minutes per 8 hours of appointments. The effect grows with how often doctors use the assistant.

For a clinic, this is a direct calculation: doctor minutes turn into extra appointments and revenue. The steps are on the page about AI effect calculation.

The study numbers come from the US, but the logic fits any clinic: doctor time spent on notes can go back into appointments. Check it on your own schedule for one month before you sign a contract.

The second payback point is reference services for doctors. OpenEvidence’s revenue of $100 million a year shows that people pay for such services.

How an assistant for doctor notes works in a Russian clinic is described on the page about AI documentation for doctors.

What a company should do

If you run a clinic, a clinic network or a laboratory, start with a process where doctor time counts in minutes. The JAMA study gives a guide: 16 minutes per 8 hours of appointments.

1. Count how many hours a week doctors spend on notes and documents.

2. Choose one process for a pilot and a metric: minutes per appointment, appointments per week, reply time to a patient.

3. Check where the supplier stores patient data and whether the solution needs medical device registration.

4. Compare the pilot effect with the price of the solution, and only then decide on scale.

This path is shorter with the AI Solutions Map: it shows the processes where AI pays back, which solution covers them, what it costs and in which order to introduce it.

Where AI money goes outside medicine is shown on the page about AI investment trends.

Sources and fact-checking

Checked by the editors on 14 October 2026.

  1. Solganick, AI M&A update YTD 2026, June 2026 (solganick.com)
  2. ComNews, citing Kama Flow, 6 October 2026 (comnews.ru)
  3. ComNews, citing Venture Guide (Moscow Venture Fund), Anna Shvetsova, 5 October 2026 (comnews.ru)
  4. Crunchbase News, Mary Ann Azevedo, 21 January 2026 (news.crunchbase.com)
  5. JAMA, “Changes in Clinician Time Expenditure and Visit Quantity With Adoption of Artificial Intelligence-Powered Scribes: A Multisite Study”, 1 April 2026 (jamanetwork.com)
  6. ComNews, 29 September 2026 (comnews.ru)

Found a mistake? Tell us

Publications

Mike Mozg

Agentic AI use cases at AT&T: nearly 500 processes now run on agents

AT&T no longer uses AI only to help staff work faster: it is rebuilding whole business processes around agents. SiliconANGLE reported on 14 November 2026 that nearly 500 agentic AI use cases at AT&T are already in production. Here is how the company rebuilds them, where a human still checks the agent, and what other large companies can take from it.

News4 min
Contact us